MCRB vs. PALI

Last updated Jun 6, 2026

MCRB (Seres Therapeutics, Inc.) and PALI (Palisade Bio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, MCRB returned -36.84%/yr vs -71.09%/yr for PALI. At a 0.16 correlation, their price movements are largely independent.

Performance

MCRB vs. PALI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MCRB achieves a -55.44% return, which is significantly lower than PALI's -25.96% return. Over the past 10 years, MCRB has outperformed PALI with an annualized return of -36.84%, while PALI has yielded a comparatively lower -71.09% annualized return.

MCRB

• 1D: -3.21%
• 1M: -14.12%
• YTD: -55.44%
• 6M: -60.20%
• 1Y: -19.44%
• 3Y*: -58.86%
• 5Y*: -55.39%
• 10Y*: -36.84%

PALI

• 1D: -9.84%
• 1M: -12.56%
• YTD: -25.96%
• 6M: -3.33%
• 1Y: 149.75%
• 3Y*: -57.30%
• 5Y*: -77.22%
• 10Y*: -71.09%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MCRB vs. PALI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MCRB Seres Therapeutics, Inc.	-55.44%	-10.47%	-40.64%	-75.00%	-32.77%	-66.00%	610.14%	-23.67%	-55.42%	2.42%
PALI Palisade Bio, Inc.	-25.96%	42.42%	-81.36%	-88.65%	-92.00%	-75.38%	-11.11%	-84.19%	-81.80%	-51.61%

Correlation

The correlation between MCRB and PALI is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (10Y) Calculated over the trailing 10-year period	0.16
Correlation (All Time) Calculated using the full available price history since Jun 29, 2015	0.16

Fundamentals

Market Cap MCRB : $63.53M PALI : $364.82M
EPS MCRB : -$5.22 PALI : -$0.35
PB Ratio MCRB : 2.40 PALI : 2.86
Total Revenue (TTM) MCRB : $1.15M PALI : $0.00
Gross Profit (TTM) MCRB : $183.00K PALI : $0.00
EBITDA (TTM) MCRB : -$47.68M PALI : -$26.58M

Return for Risk

MCRB vs. PALI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MCRB

MCRB Risk / Return Rank: 42
MCRB Sharpe Ratio Rank: 38
MCRB Sortino Ratio Rank: 46
MCRB Omega Ratio Rank: 48
MCRB Calmar Ratio Rank: 38
MCRB Martin Ratio Rank: 38

PALI

PALI Risk / Return Rank: 80
PALI Sharpe Ratio Rank: 77
PALI Sortino Ratio Rank: 83
PALI Omega Ratio Rank: 78
PALI Calmar Ratio Rank: 81
PALI Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MCRB vs. PALI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MCRB	PALI	Difference
Sharpe ratio: Return per unit of total volatility	-0.09	1.25	-1.34
Sortino ratio: Return per unit of downside risk	0.65	2.53	-1.88
Omega ratio: Gain probability vs. loss probability	1.09	1.28	-0.19
Calmar ratio: Return relative to maximum drawdown	-0.11	2.77	-2.89
Martin ratio: Return relative to average drawdown	-0.19	5.96	-6.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MCRB vs. PALI - Sharpe Ratio Comparison

The current MCRB Sharpe Ratio is -0.09, which is lower than the PALI Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of MCRB and PALI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MCRB	PALI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.09	1.25	-1.34
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.53	-0.53	0.00
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.24	-0.51	+0.27
Sharpe Ratio (All Time) Calculated using the full available price history	-0.25	-0.45	+0.20

Drawdowns

MCRB vs. PALI - Drawdown Comparison

The maximum MCRB drawdown since its inception was -99.36%, roughly equal to the maximum PALI drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for MCRB and PALI.

Drawdown Indicators

	MCRB	PALI	Difference
Max Drawdown Largest peak-to-trough decline	-99.36%	-100.00%	+0.64%
Max Drawdown (1Y) Largest decline over 1 year	-76.84%	-56.53%	-20.31%
Max Drawdown (3Y) Largest decline over 3 years	-94.64%	-98.44%	+3.80%
Max Drawdown (5Y) Largest decline over 5 years	-98.64%	-99.98%	+1.34%
Max Drawdown (10Y) Largest decline over 10 years	-99.12%	-100.00%	+0.88%
Current Drawdown Current decline from peak	-99.36%	-100.00%	+0.64%
Average Drawdown Average peak-to-trough decline	-81.41%	-76.29%	-5.12%
Ulcer Index Depth and duration of drawdowns from previous peaks	46.42%	26.26%	+20.16%

Volatility

MCRB vs. PALI - Volatility Comparison

The current volatility for Seres Therapeutics, Inc. (MCRB) is 14.03%, while Palisade Bio, Inc. (PALI) has a volatility of 23.25%. This indicates that MCRB experiences smaller price fluctuations and is considered to be less risky than PALI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MCRB	PALI	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.03%	23.25%	-9.22%
Volatility (6M) Calculated over the trailing 6-month period	66.69%	68.12%	-1.43%
Volatility (1Y) Calculated over the trailing 1-year period	102.45%	125.43%	-22.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	104.70%	145.73%	-41.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	154.15%	140.79%	+13.36%

Dividends

MCRB vs. PALI - Dividend Comparison

Neither MCRB nor PALI has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MCRB and PALI in my portfolio?

MCRB and PALI have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MCRB or PALI?

PALI has higher volatility (23.25%) compared to MCRB (14.03%). In terms of maximum drawdown, MCRB dropped -99.36% vs PALI's -100.00%.

Which has better risk-adjusted returns?

PALI currently has the higher Sharpe Ratio (1.25 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.